| Drug | Route | Weight loss* | Restrictions |
|---|---|---|---|
| Wegovy (injectable) | Weekly injection | ~14.9% | None |
| Oral Wegovy (pill) | Daily pill | ~16.6% | 30-min fast |
| Foundayo (pill) | Daily pill | ~12.4% | None |
Oral GLP-1 is here now
The Wegovy pill (semaglutide 25mg, once daily) was FDA approved December 22, 2025, and launched in the US in January 2026. In studies, people lost an average of ~16.6% body weight when taken as directed. The self-pay cost is lower too: $149–$299/month by dose, against $349–$399/mo for the injection.
See semaglutide page for full details →Why oral GLP-1s are challenging
GLP-1 drugs such as semaglutide and liraglutide are peptides. A peptide is a chain of amino acids, essentially a small protein. The digestive system is designed to break down proteins. When you swallow a peptide:
- Stomach acid immediately starts unfolding the peptide structure
- Pepsin, a stomach enzyme, starts cutting the peptide chain
- Even if it reaches the small intestine, enzymes there break it down further
- What remains is largely amino acids, not a whole drug molecule
This is why subcutaneous injection, meaning an injection under the skin, has been the standard. It delivers the drug into the lymph system and bloodstream, and skips the digestive system entirely. Semaglutide injected this way has approximately 42% bioavailability.
Solution 1: SNAC technology (oral semaglutide)
Oral semaglutide (Rybelsus) uses a chemical called SNAC (Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to sneak the drug through the stomach wall. SNAC works through three mechanisms:
pH buffering: SNAC raises the pH just around the tablet, which calms pepsin. Pepsin is the enzyme that would otherwise destroy semaglutide.
Monomerisation: Changes the local chemistry so semaglutide molecules stay separate rather than clumping. Single molecules cross the stomach lining more easily.
Membrane permeabilisation: SNAC settles for a while into the cells of the stomach lining, and lets more semaglutide through.
Bioavailability caveat: only a small share of a swallowed dose reaches the blood. It is less than 1% for oral semaglutide, against ~42% for the injection under the skin. So a much higher dose is required orally (25mg tablet vs 2.4mg injection) to get a comparable effect. It must be taken on an empty stomach with no more than 120ml (4oz) of water, at least 30 minutes before food.
Solution 2: Small molecule oral GLP-1s (Foundayo / orforglipron)
Foundayo (orforglipron, Eli Lilly, FDA approved April 2026) takes a fundamentally different approach. Oral Wegovy uses SNAC technology and requires a fasting window. Foundayo has no food or water restrictions at all. Rather than a peptide, it is a small molecule, a different class of drug entirely.
Peptide GLP-1s (semaglutide)
- Protein structure, destroyed by stomach acid
- Requires SNAC technology or injection
- Strict food timing restrictions (oral)
- Low oral bioavailability (<1%)
Small molecule (orforglipron)
- Naturally acid-stable, so it survives the gut
- No special technology needed
- No food timing restrictions
- Higher oral bioavailability
In a large study of 3,127 adults with obesity, people taking Foundayo lost an average of 12.4% body weight at 72 weeks. That is comparable to injectable GLP-1s at similar points in time. It is the first oral GLP-1 drug with no food or water timing restrictions.
FDA approved April 2026. See the full Foundayo page
The oral GLP-1 landscape in 2026
As of June 2026, there are two FDA-approved oral GLP-1 drugs for weight loss — plus one in late development:
Oral Wegovy (semaglutide 25mg)
~16.6% weight loss (with full adherence). Requires 30-minute fasting window. $149–$299/month self-pay.
Foundayo (orforglipron 36mg)
~12.4% weight loss. No food or water restrictions. $149–$349/month self-pay. Medicare Part D coverage expected July 2026.
Amycretin oral (Novo Nordisk)
Not yet approved13.1% weight loss in 12 weeks in early Phase 1 data. GLP-1 + amylin dual agonist. Phase 3 starting 2026.
The key trade-off between the two approved oral options is weight loss vs convenience. Oral Wegovy produces more weight loss but requires strict morning fasting. Foundayo produces somewhat less weight loss but can be taken any time with no restrictions.
See the full Oral Wegovy vs Foundayo comparison →Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: